Amgen : launching Repatha / / Tim Calkins, Mike Harris
(Visualizza in formato marc)
(Visualizza in BIBFRAME)
| Autore: |
Calkins Tim
|
| Titolo: |
Amgen : launching Repatha / / Tim Calkins, Mike Harris
|
| Pubblicazione: | London : , : Kellogg School of Management, , 2017 |
| Descrizione fisica: | 1 online resource : illustrations |
| Disciplina: | 616.12 |
| Soggetto topico: | Heart - Diseases - Treatment - United States |
| Hypercholesteremia | |
| Persona (resp. second.): | HarrisMike |
| Note generali: | Originally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University. |
| Sommario/riassunto: | In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast. |
| Titolo autorizzato: | Amgen |
| ISBN: | 1-5264-3112-2 |
| Formato: | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione: | Inglese |
| Record Nr.: | 9910678471803321 |
| Lo trovi qui: | Univ. Federico II |
| Opac: | Controlla la disponibilità qui |
Serie:
SAGE Knowledge. . -Cases.